SCHEMBL9544389

SCHEMBL9544389

C[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(=O)O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.54
DPP8 Q6V1X1 1/20 0.54
DPP9 Q86TI2 1/20 0.54
BACE1 P56817 14/20 0.51
CTSD P07339 4/20 0.51
GRM8 O00222 1/20 0.44
GRM6 O15303 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GSR P00390 1/20 0.44
CYP1A2 P05177 1/20 0.44
GRIK1 P39086 1/20 0.44
GRM5 P41594 1/20 0.44
GRIA1 P42261 1/20 0.44
GRIA2 P42262 1/20 0.44
GRIA3 P42263 1/20 0.44
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
GRIA4 P48058 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9544381 1.00 DPP4 (0.54) DPP4DPP8DPP9BACE1CTSD
SCHEMBL29777789 1.00 DPP4 (0.54) DPP4DPP8DPP9BACE1CTSD
SCHEMBL30463268 0.97 DPP4 (0.56) DPP4DPP8DPP9BACE1CTSD
SCHEMBL29517333 0.97 DPP4 (0.56) DPP4DPP8DPP9BACE1CTSD
SCHEMBL9293719 0.96 BACE1 (0.51) DPP4DPP8DPP9BACE1CTSD
SCHEMBL9293727 0.96 BACE1 (0.51) DPP4DPP8DPP9BACE1CTSD
SCHEMBL29777835 0.95 BACE1 (0.53) DPP4DPP8DPP9BACE1CTSD
SCHEMBL30479086 0.95 BACE1 (0.53) DPP4DPP8DPP9BACE1CTSD
SCHEMBL29777826 0.95 BACE1 (0.53) DPP4DPP8DPP9BACE1CTSD
SCHEMBL30799949 0.93 BACE1 (0.48) DPP4DPP8DPP9BACE1CTSD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034090-A1 CANNABINOID PRODRUG COMPOUNDS FIRSTLIGHT PHARMACEUTICALS LLC (US) 2026-02-05 US claimed
US-20250263437-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US claimed
CN-117209592-A Humanized type I collagen and preparation method and application thereof 浙江大学 2023-12-12 CN claimed
EP-4276105-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF Sichuan Gooddoctor Panxi Pharmaceutical Co. Ltd (CN) 2023-11-15 EP claimed
CN-116854807-A Recombinant human VII type collagen and preparation method and application thereof 浙江大学 2023-10-10 CN claimed
CN-116854808-A Humanized III type collagen and preparation method thereof 浙江大学 2023-10-10 CN claimed
CN-115369103-A Construction of high specific activity keratinase mutant and pichia pastoris expression plasmid, and strain screening and purifying method 河南合智医药科技有限公司 2022-11-22 CN claimed
CN-115011583-A High-expression high-specific-activity proteinase K mutant sequence, construction of pichia pastoris expression plasmid, and strain screening and purifying method 河南合智医药科技有限公司 2022-09-06 CN claimed
CN-114805489-A Polypeptide for repairing skin injury or mucous membrane injury and application thereof 四川好医生攀西药业有限责任公司 2022-07-29 CN claimed
WO-2022148289-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF 四川好医生攀西药业有限责任公司 2022-07-14 WO claimed
US-20260139005-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES DONALD DANFORTH PLANT SCIENCE CENTER (US) 2026-05-21 US disclosed
US-12629446-B2 Vascular embolic system 3-D MATRIX, LTD. (JP) 2026-05-19 US disclosed
US-12604903-B2 Antimicrobial NCR peptides DONALD DANFORTH PLANT SCIENCE CENTER 2026-04-21 US disclosed
US-12606600-B2 Antimicrobial NCR2 peptides DONALD DANFORTH PLANT SCIENCE CENTER (US) 2026-04-21 US disclosed
EP-4705479-A2 ANTIMICROBIAL NODULE-SPECIFIC CYSTEINE-RICH PEPTIDE FOLDING VARIANTS Donald Danforth Plant Science Center (US) 2026-03-11 EP disclosed
US-20220089661-A1 ANTIMICROBIAL PEPTIDES DONALD DANFORTH PLANT SCIENCE CENTER 2022-03-24 US disclosed
US-20220081475-A1 ANTIMICROBIAL PEPTIDES DONALD DANFORTH PLANT SCIENCE CENTER 2022-03-17 US disclosed
WO-1993009233-A2 RECOMBINANT AMYLOID PRECURSOR PROTEIN INHIBITOR DOMAIN AND TREATMENT OF VARIOUS DISEASE STATES THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES INC. (US) 1993-05-13 WO disclosed
WO-1991005057-A1 CD4 PRODUCTION IN PICHIA PASTORIS THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) 1991-04-18 WO disclosed
EP-0206783-A2 Expression and secretion of polypeptides from saccharomyces cerevisiae The Salk Institute Biotechnology Industrial Associates, Inc. (US) 1986-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260139005-A1 SYNTHETIC ANTIMICROBIAL PEPTIDES ARG1, NOS2, VIP DPP4 638/4885DPP8 1233/4885DPP9 586/4885
US-12604903-B2 Antimicrobial NCR peptides CNBP, NRDC, RNGTT DPP4 2202/4885DPP8 1577/4885DPP9 1788/4885
US-20260034090-A1 CANNABINOID PRODRUG COMPOUNDS CNR1, CNR2, FAAH DPP4 3074/4885DPP8 2553/4885DPP9 2976/4885
US-12606600-B2 Antimicrobial NCR2 peptides UPF1, NRDC, SRRT DPP4 3466/4885DPP8 3161/4885DPP9 3087/4885
US-12629446-B2 Vascular embolic system TNNI3, MYLK, ADM2 DPP4 3553/4885DPP8 4252/4885DPP9 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.